Last reviewed · How we verify
NALIRI
NALIRI is a small molecule that targets the PI3K/AKT/mTOR pathway.
NALIRI is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors.
At a glance
| Generic name | NALIRI |
|---|---|
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NALIRI works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.
Approved indications
- Advanced solid tumors
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen (PHASE2)
- A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma (PHASE2)
- Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer (PHASE3)
- A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (PHASE2)
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (PHASE2)
- Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |